MetLife Investment Management
CLYM icon

MetLife Investment Management’s Climb Bio CLYM Stock Holding History

MetLife Investment Management’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278K Buy
+21,305
New +$220K ﹤0.01% 2250
2024
Q4 		– Sell
-17,769
Closed -$90.4K – 2870
2024
Q3 		$90.4K Buy
+17,769
New +$126K ﹤0.01% 2663

Other funds holding CLYM

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Frontier Capital Management
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MetLife Investment Management's CLYM Position: Q2 2026 in Review

MetLife Investment Management opened a new position in Climb Bio (CLYM) in Q2 2026: 21,305 shares worth $278K. The stake represents ﹤0.01% of the portfolio and ranks #2250 among its holdings. This is a return to the name: MetLife Investment Management previously reported a position in CLYM as recently as Q3 2024.

MetLife Investment Management first reported a position in CLYM in Q3 2024 and has held it in 2 quarters since. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • MetLife Investment Management held 21,305 shares of Climb Bio worth $278K as of Q2 2026.
  • Climb Bio was a new MetLife Investment Management position in Q2 2026.
  • Climb Bio made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2250 holding.
  • MetLife Investment Management first reported a position in Climb Bio in Q3 2024 and has held it in 2 quarters since.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.